[ad_1]
The Firmasınca coronavac Sinovac vaccine produced in China has been completed, Coordinator of Hacettepe University Phase 3 study conducted in 24 centers in Turkey.
In a written statement from Hacettepe University, it was stated that the purpose of the Phase 3 clinical study conducted with healthy volunteers was to evaluate the safety of the CoronaVac vaccine developed against the Covid-19 pandemic and its protection against RT-confirmed disease. PCR. This study was noted to be a double-blind, placebo-controlled, randomized clinical trial, meaning that some of the volunteers received the actual vaccine and the other part received a placebo.
Noting that it is unknown what was done with which volunteer and what was done with the volunteer and the research team, “it was planned that the study protocol would include 12,450 volunteers in total, in two phases: health workers (K- 1 Cohort) and normal-risk volunteers (K-2 cohort). Health. While 1 application out of 2 vaccination applications to the K-1 cohort consisting of employees was the actual vaccine, 2 applications out of 3 vaccination applications in the normal-risk volunteer department were randomized to the vaccine arm. real, that is, the real vaccination chance for volunteers is 2/3.
’57 PERCENT OF MEN AND 43 PERCENT OF WOMEN ‘
Stating that the clinical study began with the inclusion of the first volunteer on September 14, 2020, “Volunteers aged 18 to 59 were included in two separate arms, the actual vaccine arm and the placebo arm. Six thousand 648 of These volunteers were included in the vaccine arm, while 3,568 of them were included in the placebo arm. 42.2 percent of them are women while they are men. The average age is 45. ” Expressions were used.
EFFICIENCY CALCULATED AT 83.5 PERCENT
Within the scope of the study, it was stated that blinding began to break down in healthcare workers on January 14, 2021 due to the approval of emergency use.
Then, according to the capacity of the centers, the blindness of the volunteers continued until February 12, 2021. On February 12, the blindness of all the volunteers was broken. With Covid-19 symptomatic and confirmed by RT-PCR In the cases seen to date, the effectiveness of the vaccine was calculated at 83.5 percent. The most common side effects were fatigue 9.8 percent, headache 7.6 percent, muscle pain 3.8 percent, fever 2.5 percent, chills 2.4 percent and localized. The effect is pain at the injection site, 1.6 percent. The median follow-up period after the first dose of the vaccine is 70 days, and the median follow-up period of 14 days after the second dose of the vaccine is 42 days.
MOST VISITED SIDE EFFECTS
The statement also included the most common side effects after vaccination.
It was stated that fatigue (9.8 percent), headache (7.6 percent) muscle pain (3.8 percent) fever (2.5 percent) chills (2.4 percent) and the effects The most common local side effects were injection site pain.
The vaccine began rolling out on January 14 in Turkey.
243 THOUSAND 558 COVID-19 VACCINES HAVE BEEN CARRIED OUT IN THRACE, WHERE THE INCREASE IN CASES CONTINUES
While the rise in new types of coronavirus (Kovid-19) cases continued in Thrace, Edirne was among the “very high risk” cities, Kırklareli and Tekirdağ “high risk”.
According to the number of new types of coronavirus cases (Kovid-19) corresponding to 100,000 inhabitants per week from the Ministry of Health, the number of cases in Edirne was determined at 107.43, 94.44 in Kırklareli and 85.55 in Tekirdağ.
The largest increase in the provinces of the region compared to last week was recorded in Edirne, which went from 75.29 to 107.43. In Edirne, which is among the “very high risk” provinces, restaurants, cafes and restaurants were closed within the scope of the measures.
According to data from the website “https://covid19asi.saglik.gov.tr/” of the Ministry of Health, most of the vaccines were applied in Tekirdağ with 116,833 in Thrace. 69,562 in Edirne and 57 in Kırklareli One thousand 163 vaccines were produced.
63 PERCENT OF OXFORD-ASTRAZENECA VACCINE
The World Health Organization (WHO) recommended that the Kovid-19 vaccine, developed jointly by the University of Oxford and AstraZeneca, be used in countries where new variants of the coronavirus appear.
The WHO recommended the use of the AstraZeneca vaccine, although less effective against newer variants, and noted that the vaccine could also be used in people over 65 years of age.
It was also noted that, as in the UK, the longer the time between two doses of vaccine, the more effective the vaccine was. The WHO Vaccine Advisory Council (SAGE) reviewed the vaccine trial data. Based on initial determinations, the overall effectiveness rate for the AstraZeneca vaccine was announced at 63 percent.
